Brind.

Eli Lilly Presents Combination Therapy Results for Psoriasis and Obesity

2 reports, 2 independent Updated Mon 00:00
No new developments lately
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Eli Lilly and Company presented exploratory findings from the TOGETHER-PsO Phase 3b clinical trial at the 2026 Fall Clinical Dermatology Conference in Las Vegas. The study compared the use of Taltz and Zepbound together versus Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity. The results indicated that the combination therapy produced changes in a wider range of psoriasis and metabolic biomarkers compared to Taltz monotherapy.

From prnewswire.com

Why it matters

Some supportBrind's analysis of the reports

The findings suggest an immunometabolic relationship between psoriasis and obesity. This insight could influence how medical treatments are approached for patients who suffer from both conditions, potentially expanding the scope of treatment options.

From prnewswire.com

Who's involved

  • Eli Lilly and CompanyThe pharmaceutical company that conducted and presented the clinical trial results.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • ArriveSpeculative

    Arrive could see increased demand for related health services as the addressable patient market expands.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped